Range Low Price High Price Comment
30 days $27.00 $36.72 Wednesday, 27th Mar 2024 ARWR stock ended at $28.70. This is 3.09% more than the trading day before Tuesday, 26th Mar 2024. During the day the stock fluctuated 3.63% from a day low at $27.86 to a day high of $28.87.
90 days $27.00 $39.83
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
2024-01-16 $36.03 $36.03 $34.32 $35.09 1 364 363
2024-01-12 $37.62 $37.62 $35.56 $36.43 1 481 697
2024-01-11 $39.22 $39.54 $37.36 $37.50 2 002 746
2024-01-10 $38.24 $39.83 $37.71 $39.45 1 815 122
2024-01-09 $38.91 $39.65 $37.26 $38.07 1 929 802
2024-01-08 $35.10 $39.53 $34.37 $39.48 5 163 886
2024-01-05 $33.89 $35.99 $33.32 $35.60 2 840 723
2024-01-04 $32.63 $34.80 $32.59 $34.53 4 870 028
2024-01-03 $32.65 $34.31 $31.16 $31.97 5 984 885
2024-01-02 $30.50 $32.15 $29.65 $31.01 764 917
2023-12-29 $31.22 $31.68 $30.55 $30.60 810 091
2023-12-28 $30.88 $31.57 $30.52 $31.00 888 337
2023-12-27 $31.05 $31.55 $30.53 $31.03 650 988
2023-12-26 $30.68 $31.16 $30.10 $30.89 671 390
2023-12-22 $29.00 $30.44 $29.00 $30.35 929 191
2023-12-21 $28.33 $28.90 $28.12 $28.76 976 612
2023-12-20 $29.90 $30.00 $27.77 $27.83 1 085 795
2023-12-19 $28.38 $30.09 $28.36 $30.00 1 458 540
2023-12-18 $28.59 $28.93 $27.34 $27.94 868 685
2023-12-15 $28.64 $29.48 $27.73 $28.55 2 716 028
2023-12-14 $27.53 $29.28 $27.53 $28.55 1 615 765
2023-12-13 $24.63 $26.91 $24.55 $26.90 1 597 052
2023-12-12 $23.79 $24.79 $23.06 $24.69 940 920
2023-12-11 $24.37 $24.50 $23.70 $23.87 1 108 925
2023-12-08 $24.44 $25.10 $23.92 $23.95 912 424
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT